COST EFFECTIVENESS EVALUATION OF APIXABAN, DABIGATRAN RIVAROXABAN AND WARFARIN FOR PREVENTION OF TROMBOEMBOLISM IN PATIENTS WITH ATRIAL FIBRILLATION IN TRINIDAD AND TOBAGO

被引：0
|
作者：
Garita, M. [1 ]
Peralta, M. [1 ]
Dookie, T. A. [2 ]
机构：
[1] Pfizer Cent Amer & Caribbean, San Jose, Costa Rica
[2] Westshore Med Ctr, Port Of Spain, Trinidad Tobago
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.678
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV84
引用
收藏
页码：A116 / A117
页数：2
相关论文
共 50 条
  • [1] Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
    Harrington, Amanda R.
    Armstrong, Edward P.
    Nolan, Paul E., Jr.
    Malone, Daniel C.
    [J]. STROKE, 2013, 44 (06) : 1676 - +
  • [2] COST EFFECTIVENESS OF APIXABAN, DABIGATRAN RIVAROXABAN AND WARFARIN FOR ATRIAL FIBRILLATION IN GUATEMALA
    Garita, M.
    Peralta, M.
    Gordillo, D., I
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A115 - A115
  • [3] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Chieh-Yu Liu
    Hui-Chun Chen
    [J]. Clinical Drug Investigation, 2017, 37 : 285 - 293
  • [4] Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
    Torbjørn Wisløff
    Gunhild Hagen
    Marianne Klemp
    [J]. PharmacoEconomics, 2014, 32 : 601 - 612
  • [5] Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
    Wisloff, Torbjorn
    Hagen, Gunhild
    Klemp, Marianne
    [J]. PHARMACOECONOMICS, 2014, 32 (06) : 601 - 612
  • [6] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Liu, Chieh-Yu
    Chen, Hui-Chun
    [J]. CLINICAL DRUG INVESTIGATION, 2017, 37 (03) : 285 - 293
  • [7] COST-EFFECTIVENESS OF EDOXABAN, APIXABAN, RIVAROXABAN AND DABIGATRAN VERSUS WARFARIN FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
    Marchetti, M.
    Liberato, N. L.
    Rognoni, C.
    Quaglini, S.
    [J]. HAEMATOLOGICA, 2014, 99 : 487 - 487
  • [8] Comparative Effectiveness of Dabigatran, Rivaroxaban, Apixaban, and Warfarin in the Management of Patients With Nonvalvular Atrial Fibrillation
    Pink, J.
    Pirmohamed, M.
    Hughes, D. A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (02) : 269 - 276
  • [9] Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation
    Wang, Ye
    Xie, Feng
    Kong, Ming Chai
    Lee, Lai Heng
    Ng, Heng Joo
    Ko, Yu
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2014, 28 (06) : 575 - 585
  • [10] Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation
    Ye Wang
    Feng Xie
    Ming Chai Kong
    Lai Heng Lee
    Heng Joo Ng
    Yu Ko
    [J]. Cardiovascular Drugs and Therapy, 2014, 28 : 575 - 585
12345